| Record ID | marc_records_scriblio_net/part23.dat:62387421:1405 |
| Source | Scriblio |
| Download Link | /show-records/marc_records_scriblio_net/part23.dat:62387421:1405?format=raw |
LEADER: 01405cam 2200289 a 4500
001 92247432
003 DLC
005 20000519125255.0
008 921208s1992 dcua b f000 0 eng c
010 $a 92247432
020 $a0160385512
040 $aDGPO/DLC$cDLC$dDLC
043 $an-us---
050 00 $aKF27$b.S675 1991p
086 0 $aY 4.Sm 1:102-56
110 1 $aUnited States.$bCongress.$bHouse.$bCommittee on Small Business.$bSubcommittee on Regulation, Business Opportunities, and Energy.
245 14 $aThe safety and effectiveness of the abortifacient RU486 in foreign markets :$bopportunities and obstacles to U.S. commercialization : hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred Second Congress, first session, Washington, DC, December 5, 1991.
260 $aWashington :$bU.S. G.P.O. :$bFor sale by the U.S. G.P.O., Supt. of Docs., [Congressional Sales Office],$c1992.
300 $aiii, 338 p. :$bill. ;$c24 cm.
500 $a1031-A, 1031-B (MF)
500 $aDistributed to some depository libraries in microfiche.
500 $aShipping list no.: 92-0374-P.
504 $aIncludes bibliographical references.
500 $a"Serial no. 102-56."
650 0 $aMifepristone$xEffectiveness.
650 0 $aMifepristone$xGovernment policy$zUnited States.
650 0 $aAbortifacients.